Emergent BioSolutions (EBS) Liabilities from Discontinued Operations (2015 - 2025)

Emergent BioSolutions' Liabilities from Discontinued Operations history runs 4 years deep, the most recent figure standing at 4500000.0 for Q3 2025.

• On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 4500000.0 in Q3 2025; TTM through Sep 2025 was 4500000.0, a N/A change from a year earlier, with the FY2015 full-year figure at 17348000.0, changed N/A from the prior year.
• Liabilities from Discontinued Operations slipped to 4500000.0 in Q3 2025 per EBS's latest filing, from 4700000.0 in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at 37500000.0 in Q1 2023 and bottomed at 4500000.0 in Q3 2025.
• The 3-year median for Liabilities from Discontinued Operations is 4800000.0 (2025), against an average of 12320000.0.
• Biggest YoY gain for Liabilities from Discontinued Operations was 53.47% in 2025; the steepest drop was 53.47% in 2025.
• Year by year, Liabilities from Discontinued Operations stood at 37500000.0 in 2023, then tumbled by 73.07% to 10100000.0 in 2024, then sank by 55.45% to 4500000.0 in 2025.
• Per Business Quant, the three latest EBS Liabilities from Discontinued Operations figures stand at 4500000.0 (Q3 2025), 4700000.0 (Q2 2025), and 4800000.0 (Q1 2025).